Volume 13 Supplement 1

Challenges in malaria research: Core science and innovation

Open Access

Clinical determinants of early parasitological response after ACT treatment in patients diagnosed with uncomplicated malaria in Africa: a pooled analysis of individual patient data

  • Prabin Dahal1, 2 and
  • WWARN ACT Africa Baseline Study Group1
Malaria Journal201413(Suppl 1):P24

https://doi.org/10.1186/1475-2875-13-S1-P24

Published: 22 September 2014

Background

Artemisinin resistant P. falciparum malaria has emerged in Western Cambodia and now has been observed in Thailand, Vietnam and Myanmar and Lao. In addition, there is a recent report of a Vietnamese patient, apparently infected with P. falciparum in Angola, who was unresponsive to artemisinin treatment. This makes it even more urgent to have baseline information on early parasite response to ACTs in African patients, the first step in establishing surveillance for this important phenotype.

Materials and methods

Individual patient data from efficacy trials conducted between 1999 and 2012 were shared with the Worldwide Antimalarial Resistance Network (WWARN) and pooled analyses conducted using standardized methodology. Factors affecting early parasitological response to treatment were investigated using logistic regression with study sites fitted as a random effect.

Results

Data from 85 studies (N = 29,664) conducted in 27 countries with Artemether-lumefantrine (AL, n = 13,664), Artesunate-amodia-quine-fixed dose combination (ASAQ-F; n = 4,097), Artesunate-amodiaquine-co-blister combination (ASAQ-C; n = 2,505), Artesunate-amodiaquine-loose combination (ASAQ-L; n = 4,096), and Di hydro artemisinin-piperaquine (DP; n = 4,492) were included. With all drugs tested, high baseline parasite density and fever were both independent predictors of persistent parasitemia on days 1, 2 and 3. Adjusted for these variables, patients from 1 to 5 years and from 5 to 12 years in areas of low/moderate transmission were at a 2-fold and 4-fold risk of persistent parasitemia on day 3 compared to patients of the same age-group in high transmission settings. Treatment with AL was associated with a higher risk of persistent parasitemia on day 1 (AOR = 1.57 [95% CI: 1.38-1.78], P < 0.001) and day 2 (AOR = 1.21 [95% CI: 1.01-1.45], P = 0.043) compared to treatment with DP. Treatment with ASAQ-L was also associated with a higher risk of persistent parasitemia on day 2 (AOR = 1.59 [95% CI: 1.16-2.18], P = 0.004) and day 3 (AOR = 2.62 [95% CI: 1.24-5.53], P = 0.012) compared to treatment with DP.

Conclusions

These results show no evidence of slow parasite clearance in these African studies. The greatest risk of slow clearance was observed in patients from areas of low/moderate transmission. The threshold for suspected diminished parasite susceptibility to artemisinins on day 3 was estimated to be 5%, much lower than the currently used World Health Organisation threshold of 10%. However, there are clear gaps in surveillance and any sites exceeding the day 3 parasite positivity rate of 5% should be further investigated.

Declarations

Acknowledgements

A full list of the Worldwide Antimalarial Resistance Network ACT Africa baseline study group members can be found at: http://www.wwarn.org/partnerships/study-groups/act-africa-baseline-study-group.

Authors’ Affiliations

(1)
WorldWide Antimalarial Resistance Network (WWARN)
(2)
Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford

Copyright

© Dahal and WWARN ACT Africa Baseline Study Group; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement